AAS
MTNB icon

Avantax Advisory Services’s Matinas BioPharma MTNB Stock Holding History

Avantax Advisory Services’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$13K – 1266
2021
Q3 		$13K Buy
+200
New +$8.63K ﹤0.01% 1172

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Avantax Advisory Services's MTNB Position: Q4 2021 in Review

Avantax Advisory Services sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 200 shares — an estimated $13K sold.

Avantax Advisory Services first reported a position in MTNB in Q3 2021 and held it in 1 quarter. The position peaked at $13K in Q3 2021. 66 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

  • Avantax Advisory Services reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
  • Avantax Advisory Services sold 200 Matinas BioPharma shares in Q4 2021, an estimated $13K.
  • Avantax Advisory Services first reported a position in Matinas BioPharma in Q3 2021 and held it in 1 quarter.
  • Avantax Advisory Services's Matinas BioPharma position peaked at $13K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on Avantax Advisory Services's 13F filing for Q4 2021, filed 24 Jan 2022.